Polymer-Based Hydroxyapatite-Silver Composite Resin with Enhanced Antibacterial Activity for Dental Applications

用于牙科的具有增强抗菌活性的聚合物基羟基磷灰石-银复合树脂

阅读:17
作者:Jesús Alberto Garibay-Alvarado, Diana Juana Garcia-Zamarron, Pamela Nair Silva-Holguín, Alejandro Donohue-Cornejo, Juan Carlos Cuevas-González, León Francisco Espinosa-Cristóbal, Álvaro de Jesús Ruíz-Baltazar, Simón Yobanny Reyes-López

Abstract

The primary objective of this investigation was to synthesize a resin incorporating nanoparticles of hydroxyapatite and silver (HA-NpsAg) to enhance biocompatibility and antimicrobial efficacy, thereby facilitating potential implementation within the dental industry. These enhancements aim to ensure reliable, durable, functional, and aesthetically pleasing restorations while concurrently reducing susceptibility to bacterial colonization within the oral cavity. Hydroxyapatite powders were prepared using the sol-gel method and doped with silver nanoparticles obtained by chemical reduction. The crystalline amorphous calcium phosphate powder had a particle size of 279 nm, and the silver nanoparticles had an average diameter of 26.5 nm. Resin spheres containing HA-NpsAg (RHN) were then synthesized at two concentrations (0.5% and 1%) by dissolving the initial monomer mixture in tetrahydrofuran. Subsequent antimicrobial evaluations were conducted via agar diffusion and turbidimetry, employing three strains of Gram-negative bacteria (E. coli, K. oxytoca, and P. aeruginosa) and three strains of Gram-positive bacteria (S. mutans, S. aureus, and B. subtilis). The findings revealed that P. aeruginosa exhibited maximum susceptibility to RHN powder at a concentration of 0.5%, while RHN powder at 1% concentration demonstrated maximal inhibition against S. aureus and S. mutans. Overall, our study highlights the successful synthesis of a dental resin with hydroxyapatite and silver nanoparticles, exhibiting bactericidal properties at low silver concentrations. These findings hold promise for enhancing dental materials with improved antimicrobial efficacy and clinical performance.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。